Patent · US Active

Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using the same

US11021520B2 · kind B2 · utility

0Cited by
6References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 6, 2018
Grant dateJun 1, 2021
Priority date
Expiry dateOct 20, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2760/18534
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode an RSV immunogen are disclosed. Nucleic acids are disclosed that comprise the sequences that encodes consensus RSV F protein or immuno-genic fragment thereof, sequences that encodes an RSV G(A) protein or immunogenic fragment thereof and sequences that encodes an RSV G(B) protein or immunogenic fragment thereof. Compositions comprising one, combinations of two or all three sequences are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Nucleic acid molecules and compositions comprising the chemokine CC20 and/or a consensus RSV M2-1 protein or immunogenic fragment thereof are also disclosed. Immunomodulatory methods and methods of inducing an immune response against RSV are disclosed. Methods of preventing RSV infection and methods of treating individuals infected with RSV are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.